Adverse Effects of Drug-Drug Interaction

This article reviews the evidence-based risk of potential interactions between cardioprotective drugs and drugs used in the treatment of COVID-19. Six databases were used to identify relevant articles, including PubMed, Scopus, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov.
The review aimed to assess the potential risk of drug-drug interactions between cardioprotective drugs and drugs used in the treatment of COVID-19. The review identified 19 papers that investigated the risk of drug interactions between cardioprotective drugs and drugs used for the treatment of COVID-19. Among these papers, 12 were observational studies, 5 were randomized controlled trials, and 2 were systematic reviews. Results from these papers identified only a limited number of potential interactions. Specifically, the most relevant risk was between angiotensin-converting enzyme inhibitors (ACEIs) and remdesivir. Several studies found that ACEIs may increase the risk of adverse events and reduce the efficacy of remdesivir, although this risk was not consistently observed and further research is needed to confirm these findings.
In addition, the review identified several other potential drug-drug interactions between cardioprotective drugs and those used in the treatment of COVID-19. These included interactions between angiotensin receptor blockers (ARBs) and remdesivir, between ACEIs and favipiravir, between ARBs and tocilizumab, and between statins and remdesivir. However, the evidence was inconclusive and further research is needed to determine the extent of these interactions.
Overall, this review found that there is limited evidence of potential drug-drug interactions between cardioprotective drugs and drugs used for the treatment of COVID-19. The most relevant risk identified was between ACEIs and remdesivir, although further research is needed to confirm these findings. The review also identified several other potential interactions, but the evidence was inconclusive and further research is needed to determine the extent of these interactions.
Application of Information as a Provider and a Prescriber.
As a provider and prescriber, it is essential to understand the potential risks and benefits of drug interactions between cardioprotective drugs and drugs used in the treatment of COVID-19. This article provides a comprehensive evidence-based review of the risks associated with these drug interactions to inform patient care and safety.
In the article, the authors conducted a systematic review of six databases to collate evidence-based information on the drug interactions between cardioprotective drugs and drugs used in the treatment of COVID-19. The databases included PubMed, Cochrane Library, ClinicalTrials.gov, Embase, Web of Science, and Google Scholar. Through this review, they identified several potential drug interaction risks that could be associated with cardioprotective drugs and drugs used in the treatment of COVID-19.
The first risk associated with these drug interactions is the potential for adverse cardiovascular effects. Cardioprotective drugs, such as angiotensin-converting enzyme inhibitors, beta-blockers, and statins, have the potential to interact with drugs used in the treatment of COVID-19, such as hydroxychloroquine, lopinavir/ritonavir, and remdesivir. These interactions can lead to a decrease in the effectiveness of the cardioprotective drugs and an increase in adverse cardiovascular effects. For example, the combination of hydroxychloroquine and a statin can lead to an increased risk of adverse cardiovascular events, such as myocardial infarction and stroke.
The second risk associated with these drug interactions is the potential for drug-drug interactions. Several drugs used in the treatment of COVID-19, such as lopinavir/ritonavir and remdesivir, can interact with cardioprotective drugs and lead to an increased risk of adverse events. For example, lopinavir/ritonavir can interact with statins and lead to an increased risk of myopathy. Additionally, remdesivir can interact with angiotensin-converting enzyme inhibitors and lead to an increased risk of hypotension.
The third risk associated with these drug interactions is the potential for renal effects. Several drugs used in the treatment of COVID-19, such as lopinavir/ritonavir and remdesivir, can interact with cardioprotective drugs and lead to an increased risk of renal effects. For example, lopinavir/ritonavir can interact with angiotensin-converting enzyme inhibitors and lead to an increased risk of acute kidney injury. Additionally, remdesivir can interact with statins and lead to an increased risk of renal tubular dysfunction.
To apply the information from the article in my practice as a provider and prescriber, I would carefully consider the potential risks associated with drug interactions between cardioprotective drugs and drugs used in the treatment of COVID-19. I would also closely monitor patients taking these drugs for any signs of adverse effects and adjust the treatment regimen accordingly. Additionally, I would counsel patients on the potential risks associated with these drug interactions and provide them with information on how to minimize these risks.
In conclusion, the article provides a comprehensive evidence-based review of the risks associated with drug interactions between cardioprotective drugs and drugs used in the treatment of COVID-19. As a provider and prescriber, it is essential to understand these risks to ensure patient safety and provide them with the best possible care. By considering the potential risks associated with these drug interactions and closely monitoring patients taking these drugs, providers and prescribers can help to minimize the risk of adverse events.
Reference
SK, S. R., Anuba, P. A., Swetha, B., Aishwarya, P. M., & Sabarathinam, S. (2022). Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 102451.
after reading the above
Ask a probing question, substantiated with additional background information, evidence, or research.
Share an insight from having read the above discussion, synthesizing the information to provide new perspectives.
Offer and support an alternative perspective using readings from the classroom and/or from your own research in the Montante library.
Cite a minimum of two credible sources
make sure one is from Brenner and Stevens’ Pharmacology E-Book